REGENXBIO Inc. (RGNX)

NASDAQ: RGNX · Real-Time Price · USD

6.35

-0.40 (-5.93%)

At close: May 22, 2026, 4:00 PM EDT

6.42

+0.07 (1.10%)

After-hours: May 22, 2026, 7:28 PM EDT

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Development & Commercialization of Gene Therapies to Treat an Array of Diseases	170.44M	83.33M	90.24M	112.72M	470.35M
Development & Commercialization of Gene Therapies to Treat an Array of Diseases Growth	104.54%	-7.66%	-19.94%	-76.03%	204.30%
Total	170.44M	83.33M	90.24M	112.72M	470.35M
Total Growth	104.54%	-7.66%	-19.94%	-76.03%	204.30%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Japan	74.99M	-	-	-	-
United States	42.61M	30.00M	28.88M	39.45M	32.92M
United States Growth	42.04%	3.88%	-26.81%	19.83%	-73.37%
Germany	-	8.33M	-	11.27M	-
United Arab Emirates	-	8.33M	-	-	-
Foreign	52.84M	36.66M	61.36M	62.00M	65.85M
Foreign Growth	44.11%	-40.25%	-1.02%	-5.85%	113.01%
Bermuda	-	-	-	-	371.57M
Total	170.44M	83.33M	90.24M	112.72M	470.35M
Total Growth	104.54%	-7.66%	-19.94%	-76.03%	204.30%

Source: S&P Global Market Intelligence.